相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer
Siang-Boon Koh et al.
CLINICAL CANCER RESEARCH (2021)
Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel
Helen S. Mueller et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators A Phase 2 Randomized Clinical Trial
Ying Fan et al.
JAMA ONCOLOGY (2021)
Tumor Microenvironment in Breast Cancer-Updates on Therapeutic Implications and Pathologic Assessment
Joshua J. Li et al.
CANCERS (2021)
Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in PremenopausalWomen Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators A Phase 2 Randomized Clinical Trial
Ying Fan et al.
JAMA ONCOLOGY (2021)
Collateral sensitivity of natural products in drug-resistant cancer cells
Thomas Efferth et al.
BIOTECHNOLOGY ADVANCES (2020)
FAK signaling in cancer-associated fibroblasts promotes breast cancer cell migration and metastasis by exosomal miRNAs-mediated intercellular communication
Hsin-Jung Wu et al.
ONCOGENE (2020)
Cancer associated fibroblast FAK regulates malignant cell metabolism
Fevzi Demircioglu et al.
NATURE COMMUNICATIONS (2020)
FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer
Sonia Zaghdoudi et al.
EMBO MOLECULAR MEDICINE (2020)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Tumor Angiogenesis Is Differentially Regulated by Phosphorylation of Endothelial Cell Focal Adhesion Kinase Tyrosines-397 and-861
Ana-Rita Pedrosa et al.
CANCER RESEARCH (2019)
The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review
Jin Zhou et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial
Christina Lee Chung et al.
GEROSCIENCE (2019)
Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling
Minhong Shen et al.
CANCER CELL (2019)
Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis
Brittelle E. Kessler et al.
ONCOGENE (2019)
Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer
Martin Schwill et al.
SCIENCE SIGNALING (2019)
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
Sonia Pernas et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro
Valentina Citi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
High collagen density augments mTOR-dependent cancer stem cells in ER alpha plus mammary carcinomas, and increases mTOR-independent lung metastases
Michael P. Shea et al.
CANCER LETTERS (2018)
Role of mTOR Signaling in Tumor Microenvironment: An Overview
Fabiana Conciatori et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus
Claudia Omarini et al.
BIOMED RESEARCH INTERNATIONAL (2018)
Phenotypic Basis for Matrix Stiffness-Dependent Chemoresistance of Breast Cancer Cells to Doxorubicin
M. Hunter Joyce et al.
FRONTIERS IN ONCOLOGY (2018)
Every step of the way: integrins in cancer progression and metastasis
Hellyeh Hamidi et al.
NATURE REVIEWS CANCER (2018)
Targeting the Breast Cancer Kinome
Samantha M. Miller et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2017)
Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer
Zongbi Yi et al.
JOURNAL OF BREAST CANCER (2017)
Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition
Mei Hua Jin et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition
Sang-Oh Yoon et al.
MOLECULAR CELL (2017)
Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping
Xiaofeng Dai et al.
JOURNAL OF CANCER (2017)
PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom?
Francesco Schettini et al.
BREAST CARE (2017)
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer
Ariella B. Hanker et al.
CANCER RESEARCH (2017)
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer
Eiki Ichihara et al.
CANCER RESEARCH (2017)
The extracellular matrix in breast cancer
Jacob Insua-Rodriguez et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
The PI3K/AKT Pathway as a Target for Cancer Treatment
Ingrid A. Mayer et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts
Nils Heits et al.
BMC CANCER (2016)
The therapeutic potential of mTOR inhibitors in breast cancer
Linda S. Steelman et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
Angel Guerrero-Zotano et al.
CANCER AND METASTASIS REVIEWS (2016)
Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia
Pei-Jie Shi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response
Sara A. Hurvitz et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
Giovanni Ciriello et al.
CELL (2015)
Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumourchemoresistance
Camille Duluc et al.
EMBO MOLECULAR MEDICINE (2015)
Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors
Rony A. Francois et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
FAK signaling in human cancer as a target for therapeutics
Brian Y. Lee et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Epithelial to mesenchymal transition is associated with rapamycin resistance
Ashley M. Holder et al.
ONCOTARGET (2015)
FAK Mediates a Compensatory Survival Signal Parallel to PI3K-AKT in PTEN-Null T-ALL Cells
Dewen You et al.
CELL REPORTS (2015)
Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
Timothy J. Stuhlmiller et al.
CELL REPORTS (2015)
Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors
Rony A. Francois et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Rapamycin reduces fibroblast proliferation without causing quiescence and induces STAT5A/B-mediated cytokine production
Zoe E. Gillespie et al.
NUCLEUS (2015)
Rapamycin reduces fibroblast proliferation without causing quiescence and induces STAT5A/B-mediated cytokine production
Zoe E. Gillespie et al.
NUCLEUS (2015)
Understanding the Roles of FAK in Cancer: Inhibitors, Genetic Models, and New Insights
Hyunho Yoon et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2015)
Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors
Steven T. Sizemore et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Combined SFK/mTOR Inhibition Prevents Rapamycin-Induced Feedback Activation of AKT and Elicits Efficient Tumor Regression
Jennifer L. Yori et al.
CANCER RESEARCH (2014)
p70 Ribosomal protein S6 kinase (Rps6kb1): an update
Farnaz Bahrami-B et al.
JOURNAL OF CLINICAL PATHOLOGY (2014)
Basal-Like and Triple-Negative Breast Cancers Searching for Positives Among Many Negatives
Prasanna Alluri et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2014)
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
Elisavet Paplomata et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2014)
Targeting PI3K/Akt/mTOR signaling in cancer
Camillo Porta et al.
FRONTIERS IN ONCOLOGY (2014)
FAK in cancer: mechanistic findings and clinical applications
Florian J. Sulzmaier et al.
NATURE REVIEWS CANCER (2014)
Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases
David Lebwohl et al.
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN USA 2012 (2013)
Everolimus in hormone receptor-positive advanced breast cancer: Targeting receptor-based mechanisms of resistance
Mikhail I. Shtivelband
BREAST (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Collateral sensitivity as a strategy against cancer multidrug resistance
Kristen M. Pluchino et al.
DRUG RESISTANCE UPDATES (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
A New Mouse Model for the Study of Human Breast Cancer Metastasis
Elizabeth Iorns et al.
PLOS ONE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
ConsensusPathDB: toward a more complete picture of cell biology
Atanas Kamburov et al.
NUCLEIC ACIDS RESEARCH (2011)
Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies
Semir Vranic et al.
ONCOLOGY LETTERS (2011)
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Vanessa S. Rodrik-Outmezguine et al.
CANCER DISCOVERY (2011)
beta 1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib
Catherine Huang et al.
BREAST CANCER RESEARCH (2011)
HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment
Britta Weigelt et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Endothelial FAK is required for tumour angiogenesis
Bernardo Tavora et al.
EMBO MOLECULAR MEDICINE (2010)
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Aleix Prat et al.
BREAST CANCER RESEARCH (2010)
mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
Heidi A. Lane et al.
CLINICAL CANCER RESEARCH (2009)
ConsensusPathDB-a database for integrating human functional interaction networks
Atanas Kamburov et al.
NUCLEIC ACIDS RESEARCH (2009)
Rapamycin inhibits multiple stages of c-Neu/ErbB2-induced tumor progression in a transgenic mouse model of HER2-positive breast cancer
Jonathan D. Mosley et al.
MOLECULAR CANCER THERAPEUTICS (2007)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The role of focal-adhesion kinase in cancer. A ew therapeutic opportunity
GW McLean et al.
NATURE REVIEWS CANCER (2005)
Determinants of rapamycin sensitivity in breast cancer cells
WC Noh et al.
CLINICAL CANCER RESEARCH (2004)
Integrin signalling during tumour progression
WJ Guo et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway
D Shegogue et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes
VK Mootha et al.
NATURE GENETICS (2003)
分享论文
